ライフサイエンスコーパス: cyclin-dependent kinase 4

1 tinoblastoma kinase activity associated with cyclin-dependent kinase 4.

2 products: p16, alternate reading frame, and cyclin-dependent kinase 4.

3 three prior anticancer therapies, including cyclin-dependent kinase 4,6 inhibitors (CDK4/6i; 52%), S

4 the well-established benefit with first-line cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors be stre

5 Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followe

6 ated that NF1(low) tumors exhibited elevated cyclin-dependent kinase 4/6 (CDK4/6) activity.

7 EGFR-amplified tumours and a combination of cyclin-dependent kinase 4/6 (CDK4/6) and EGFR inhibitors

8 toma (Rb) protein [a target of the cyclin D1/cyclin-dependent kinase 4/6 (cdk4/6) holoenzyme] was del

9 Many older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an ar

10 We aimed to develop a radiolabeled cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for breas

11 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an e

12 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are appr

13 ), mammalian target of rapamycin (mTOR), and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors between

14 rotoxicity, we show that the G1/S-regulating cyclin-dependent kinase 4/6 (CDK4/6) pathway is activate

15 d efficacy in combination with inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), estrogen receptor

16 (PD), an FDA-approved selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), prevents radiation

17 ate, and are more sensitive to inhibition of cyclin-dependent kinase 4/6 (Cdk4/6).

18 ls are highly sensitive to the inhibition of cyclin-dependent kinase 4/6 (CDK4/6).

19 D3 induction to specifically block cyclin D3-cyclin-dependent kinase 4/6 assembly.

20 ion, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resista

21 Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents i

22 vestigated, including in patients with prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and/or f

23 antitumor activity, alone or combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in ESR1-

24 The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistan

25 The cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) ribocicl

26 Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with end

27 the PI3Kalpha inhibitor alpelisib and/or the cyclin-dependent kinase 4/6 inhibitor ribociclib, in xen

28 AR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting.

29 AR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting.

30 rm future systemic interventions in the post-cyclin-dependent kinase 4/6 inhibitor setting.

31 fulvestrant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), adding periodic

32 y visceral versus nonvisceral disease, prior cyclin-dependent kinase 4/6 inhibitor, and prior fulvest

33 ion phenotype was reversed by treatment with cyclin-dependent kinase 4/6 inhibitor, PD0332991/palboci

34 had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median

35 synergized with approved anti-estrogens and cyclin-dependent kinase 4/6 inhibitors (CDK4/6(i)).

36 Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in com

37 Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indic

38 Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are oral

39 BC treated with ET in combination with a TT (cyclin-dependent kinase 4/6 inhibitors [CDK4/6is], evero

40 the palbociclib plus ET arm (33.0%) received cyclin-dependent kinase 4/6 inhibitors after recurrence.

41 combination of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/6 inhibitors.

42 nt T cells with palbociclib, an inhibitor of cyclin-dependent kinase 4/6, restored cytotoxic function

43 Inactivation of both the pRb (pRb-cyclin D1/cyclin-dependent kinase 4/6-p16) and p53 (p53-p21(WAF1)-

44 s endogenous pRb phosphorylation by cyclin D-cyclin-dependent kinase 4/6.

45 rated previously that the cell cycle-related cyclin-dependent kinase 4/6/retinoblastoma protein pathw

46 e Food and Drug Administration-approved CDK (cyclin-dependent kinase) 4/6 inhibitor (CDK4/6i) palboci

47 phosphatidylinositol-3 kinase (PI3K) and/or cyclin-dependent kinases 4/6 (CDK4/6).

48 Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus en

49 east cancer following disease progression on cyclin-dependent kinases 4/6 inhibitors.

50 cell cycle inhibitors Ink4a/b (inhibitors of cyclin-dependent kinase 4 A and B), the upregulation of

51 The p16(INK4a) protein inhibits cyclin-dependent kinase 4, a key regulator of progressio

52 ogen receptor by cyclin D1 is independent of cyclin-dependent kinase 4 activation.

53 ns by DNA damage identified Sertad1, a Cdk4 (cyclin-dependent kinase 4) activator.

54 ived of matrix contact, leading to a loss of cyclin-dependent kinase 4 activity and accumulation of h

55 Additionally, cyclin-dependent kinase-4 activity was decreased in asso

56 tibility genes in the human, Inhibitor A of [cyclin-dependent] kinase 4-alternative reading frame (IN

57 gene encoding the tumor suppressor inhibitor cyclin-dependent kinase 4/alternative reading frame (Ink

58 ient in the tumor suppressors inhibitor A of cyclin-dependent kinase 4/alternative reading frame resu

59 Kinase inhibitors against Cyclin Dependent Kinase 4 and 6 (CDK4/6i) are promising

60 siRNA decreased the expression of cyclin D1, cyclin dependent kinase 4 and 6, and increased the expre

61 Cyclin D1 is a regulatory subunit of -Cyclin Dependent Kinases 4 and 6 (CDK4/6) and regulates

62 ensitive and resistant to ribociclib-induced cyclin-dependent kinase 4 and 6 (CDK4/6) inhibition.

63 ly sensitive to the combination of a BCR and cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor both

64 Finally, we show that the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor PD033

65 Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus

66 ly the combination of endocrine therapy with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors.

67 Identification of cyclin-dependent kinase 4 and 6 (CDK4/6) pathway gene al

68 The aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway plays a

69 xpression that results in hyperactivation of cyclin-dependent kinase 4 and 6 (CDK4/6), rather than by

70 The p16 tumor suppressor specifically blocks cyclin-dependent kinase 4 and 6 activity.

71 be superior to anastrozole in the absence of cyclin-dependent kinase 4 and 6 inhibition for this pati

72 Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for a

73 The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in

74 Combination therapy with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i: pal

75 iously treated with aromatase inhibitors +/- cyclin-dependent kinase 4 and 6 inhibitors were randomly

76 Cyclin-dependent kinase 4 and 6 inhibitors with endocrin

77 ion of adjuvant systemic therapies (eg, with cyclin-dependent kinase 4 and 6 inhibitors) is now indic

78 the levels of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 and associated cyclins A, E, a

79 LPTs failed to upregulate cyclin-dependent kinase 4 and cyclin D3, but Rb phosphor

80 as the associated cyclin-dependent kinases, cyclin-dependent kinase 4 and cyclin-dependent kinase 6.

81 ssociated with binding of the p16 protein to cyclin-dependent kinase 4 and dephosphorylation of pRb.

82 ell division is regulated by the activity of cyclin-dependent kinase 4 and its obligate activating pa

83 two important regulators of the cell cycle, cyclin-dependent kinase-4 and its inhibitor p16, are inc

84 Consequently, cyclin D1 and cyclin-dependent kinases 4 and 2 (CDK4 and CDK2, respect

85 Both cyclin-dependent kinases 4 and 2 regained catalytic acti

86 se to homocysteine treatment, cyclin D1, and cyclin-dependent kinases 4 and 2 translocated to the nuc

87 hippocampal cell line, H19-7, that expresses cyclin-dependent kinases 4 and 5 (cdk4 and -5).

88 Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) and the

89 lity gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose k

90 assembly with their catalytic partners, the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), into a

91 gulation of cyclin D1 which, in complex with cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), is a c

92 etic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inacti

93 Cyclin-dependent kinases 4 and 6 (CDK4/6) are central re

94 Cyclin-dependent kinases 4 and 6 (CDK4/6) are critical f

95 Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial in

96 Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamenta

97 Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regula

98 We identify cyclin-dependent kinases 4 and 6 (CDK4/6) as essential r

99 The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentia

100 Cyclin-dependent kinases 4 and 6 (CDK4/6) drive progress

101 Cyclin-dependent kinases 4 and 6 (CDK4/6) in complex wit

102 e entry in cells arrested by pharmacological cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition (Pa

103 Targeting cyclin-dependent kinases 4 and 6 (CDK4/6) is a successfu

104 Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prev

105 Activation of cyclin-dependent kinases 4 and 6 (cdk4/6) occurs in the

106 Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate

107 Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal

108 Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule

109 The cyclin-dependent kinases 4 and 6 (Cdk4/6) that control t

110 The cyclin-dependent kinases 4 and 6 (Cdk4/6) that drive pro

111 A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly s

112 rmation of enzymatically active complexes of cyclin-dependent kinases 4 and 6 (CDK4/6) with D-type cy

113 tor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)-p16-Rb pathway

114 which ultimately leads to the activation of cyclin-dependent kinases 4 and 6 (Cdk4/6).

115 Selective inhibitors that target cyclin-dependent kinases 4 and 6 (CDK4/6i) are approved

116 cyclin D promote cell division by activating cyclin-dependent kinases 4 and 6 (hereafter, CDK4/6), wh

117 Cyclin-dependent kinases 4 and 6 are complexed with many

118 Inhibitors of cyclin-dependent kinases 4 and 6 have been shown to be c

119 ndmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical tria

120 (HER2) therapies in the adjuvant setting and cyclin-dependent kinases 4 and 6 inhibitors in the metas

121 ge cells, as seen with inhibition of CDK4/6 (cyclin-dependent kinases 4 and 6) function, and dysregul

122 on with HER2-targeted therapy, inhibitors of cyclin-dependent kinases 4 and 6, angiogenesis inhibitor

123 to and inhibiting the pRb kinase activity of cyclin-dependent kinases 4 and 6.

124 The tumor suppressor p16(INK4a) inhibits cyclin-dependent kinases 4 and 6.

125 to 9p21, p15 and p16, encode inhibitors for cyclin-dependent kinases 4 and 6.

126 -specific cyclins (cyclin A, D1, and D3) and cyclin-dependent kinases 4 and 6.

127 se p19(Arf)], designated INK4A (inhibitor of cyclin dependent kinase 4) and ARF (alternative reading

128 -inhibitory disulfide bond in cyclin D-CDK4 (cyclin-dependent kinase 4) and investigate its role in c

129 lies whom we tested for mutations in CDKN2A, cyclin-dependent kinase 4, and alternate reading frame.

130 Cyclin D1, cyclin-dependent kinase 4, and c-Myc were strongly incre

131 A complex with cyclin D3, cyclin-dependent kinase 4, and C/EBPalpha was observed a

132 other Hsp client proteins, including Raf-1, cyclin-dependent kinase 4, and epidermal growth factor r

133 e gene MTS1 encodes p16INK4, an inhibitor of cyclin-dependent kinase 4, and is frequently deleted, mu

134 Immunocomplex kinase assays with cyclin-dependent kinase 4 antiserum indicate that Tax bl

135 4-alternative reading frame (INK4A-ARF) and cyclin-dependent kinase 4, are involved in the regulatio

136 pe-like secondary and tertiary structure and cyclin-dependent kinase 4 binding activity.

137 esult of up-regulation of both cyclin D1 and cyclin-dependent kinase 4 by the HCV NS5A polypeptide.

138 (4F; CDK1 [cyclin-dependent kinase 1], CDK4 [cyclin-dependent kinase 4], CCNB [cyclin B1], and CCND [

139 Cyclin dependent kinase 4 (cdk4) activity is controlled

140 ermore, RAPA decreased the protein levels of cyclin dependent kinase 4 (CDK4) and increased the expre

141 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identif

142 g the induction of cyclin D1 mRNA levels and cyclin dependent kinase 4 (CDK4)-cyclin D1 activity.

143 high-grade astrocytomas is amplification of cyclin dependent kinase-4 (CDK4).

144 ested cells in late G(1) prior to detectable cyclin-dependent kinase 4 (cdk4) activation.

145 The cyclin-dependent kinase 4 (CDK4) amplicon is frequently

146 Amplification of chromosome 12q13-q15 (Cyclin-dependent kinase 4 (CDK4) amplicon) is frequently

147 atic decrease in the levels of cyclin D1 and cyclin-dependent kinase 4 (cdk4) and accompanied by an i

148 sion of cyclin D1, A2, and E, the persistent cyclin-dependent kinase 4 (CDK4) and CDK2 activities, an

149 This was shown by activation of cyclin-dependent kinase 4 (Cdk4) and Cdk2 and by the ind

150 cell cycle requires sequential activation of cyclin-dependent kinase 4 (cdk4) and cdk2, which phospho

151 proinflammatory signaling pathway driven by cyclin-dependent kinase 4 (CDK4) and CDK6 and the methyl

152 Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical m

153 Cyclin-dependent kinase 4 (CDK4) and CDK6 are key cell-c

154 Dysregulation of cyclin-dependent kinase 4 (CDK4) and CDK6 by gain of fun

155 Cyclin-dependent kinase 4 (Cdk4) and Cdk6, and later Cdk

156 ten dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracte

157 urally distinct small molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, we have demon

158 the INK4 protein family specifically inhibit cyclin-dependent kinase 4 (cdk4) and cdk6-mediated phosp

159 al muscle myotubes (HSMMs), up-regulation of cyclin-dependent kinase 4 (CDK4) and concomitant phospho

160 ed cells requires expression and activity of cyclin-dependent kinase 4 (cdk4) and consequent de-repre

161 ses in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1),

162 her with a decrease (up to 98%; P < 0.01) in cyclin-dependent kinase 4 (CDK4) and cyclin D1 protein l

163 We find that the cell cycle molecule cyclin-dependent kinase 4 (cdk4) and its downstream effe

164 elanoma cell lines with co-overexpression of cyclin-dependent kinase 4 (CDK4) and KIT.

165 Increased expression of cyclin-dependent kinase 4 (CDK4) and loss of p16(Ink4a)

166 alters key biological pathways including the cyclin-dependent kinase 4 (CDK4) and phosphorylated reti

167 d by expression of the nononcogenic proteins cyclin-dependent kinase 4 (Cdk4) and the catalytic compo

168 transfer (TR-FRET) assay for protein kinase cyclin-dependent kinase 4 (CDK4) and the identification

169 Cyclin D and cyclin-dependent kinase 4 (cdk4) are overexpressed in a

170 Network modeling pinpointed cyclin-dependent kinase 4 (CDK4) as a key driver of this

171 Application of ReACT to oncoprotein cyclin-dependent kinase 4 (CDK4) as a representative hig

172 2D cells arrest in G(1) with active cyclin D-cyclin-dependent kinase 4 (Cdk4) but with inactive cycli

173 e that polyamines promote the translation of cyclin-dependent kinase 4 (CDK4) by the action of CUG-bi

174 Although cyclin D2-cyclin-dependent kinase 4 (cdk4) complexes mediate early

175 Although p27 associates with cyclin D-cyclin-dependent kinase 4 (cdk4) constitutively, whether

176 retinoblastoma protein phosphorylation, and cyclin-dependent kinase 4 (Cdk4) expression.

177 s of gene expression, we have identified the cyclin-dependent kinase 4 (CDK4) gene as a transcription

178 Among the genes regulated by Myc is the cyclin-dependent kinase 4 (CDK4) gene.

179 we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biolo

180 the involvement of the D-type cyclin partner cyclin-dependent kinase 4 (CDK4) in epithelial growth an

181 Overexpressing cyclin-dependent kinase 4 (Cdk4) in human epidermal kera

182 e expression of TGF-beta RII, cyclin D1, and cyclin-dependent kinase 4 (Cdk4) in Min/+ mouse intestin

183 nhibitor p16INK4A (P16) and gankyrin bind to cyclin-dependent kinase 4 (CDK4) in similar fashion, onl

184 To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, we have target

185 ransition, while it also binds and activates cyclin-dependent kinase 4 (CDK4) independent of the inhi

186 ent to promote cell cycle progression unless cyclin-dependent kinase 4 (cdk4) is also elevated, in th

187 Cyclin-dependent kinase 4 (CDK4) is well-known for its r

188 ermore, chemical inhibition of the cyclin D1/cyclin-dependent kinase 4 (CDK4) kinase complex, used as

189 lexes which detectably interact neither with cyclin-dependent kinase 4 (CDK4) nor with DNA.

190 etically engineered to express cyclin D3 and cyclin-dependent kinase 4 (CDK4) phosphorylated GST fuse

191 uced an increase in cyclin D1, cyclin E, and cyclin-dependent kinase 4 (cdk4) protein levels in a bFG

192 The mechanism by which cyclin-dependent kinase 4 (CDK4) regulates cell cycle pr

193 assays, we showed that IkappaBalpha binds to cyclin-dependent kinase 4 (CDK4) specifically and inhibi

194 to target different immunogenic mutations in cyclin-dependent kinase 4 (CDK4) that naturally occur in

195 Here we show that MyoD can interact with cyclin-dependent kinase 4 (cdk4) through a conserved 15

196 synthesis of cyclin D1 and its assembly with cyclin-dependent kinase 4 (CDK4) to form an active compl

197 tion of cyclin-dependent kinase 2 (cdk2) and cyclin-dependent kinase 4 (cdk4) were delayed during pro

198 ociation of cell-cycle proteins p27(kip) and cyclin-dependent kinase 4 (CDK4) with Cdc42; and phospho

199 Cyclin-dependent kinase 4 (CDK4), an antagonist of retin

200 ated ERalpha, AIB1, pMAPK, HER-2, cyclin D1, cyclin-dependent kinase 4 (CDK4), and Bcl2 and up-regula

201 ulatory proteins, D-type and E-type cyclins, cyclin-dependent kinase 4 (Cdk4), and Cdk2.

202 increased expression of the early G1 kinase, cyclin-dependent kinase 4 (cdk4), and one of its regulat

203 lity of T cells to up-regulate cyclin D3 and cyclin-dependent kinase 4 (cdk4), but not cdk6, resultin

204 cer (HCC) with markedly increased cyclin D1, cyclin-dependent kinase 4 (Cdk4), c-Myc and MDM2 express

205 cell cycle regulatory cascade that includes cyclin-dependent kinase 4 (cdk4), cyclin D1, and pRb (re

206 Cyclin D1, along with its main partner cyclin-dependent kinase 4 (Cdk4), is a pivotal cell cycl

207 Whereas cyclin D1b interacts with cyclin-dependent kinase 4 (CDK4), it is relatively ineff

208 immunofluorescent staining and expression of cyclin-dependent kinase 4 (Cdk4), p27(Kip1) (p27), phosp

209 udied function of cyclin D1 is activation of cyclin-dependent kinase 4 (CDK4), promoting progression

210 Although cyclin D1 binds and activates cyclin-dependent kinase 4 (Cdk4), thereby mediating acti

211 In this report, we identify the Drosophila cyclin-dependent kinase 4 (Cdk4), which exhibits embryon

212 Cyclin D1 formed complexes primarily with cyclin-dependent kinase 4 (cdk4), which were markedly ac

213 ort that in mice insulin activates cyclin D1-cyclin-dependent kinase 4 (Cdk4), which, in turn, increa

214 iR-497/195 overexpression, and we identified cyclin-dependent kinase 4 (CDK4)- and cyclin-D3 (CCND3)-

215 TRIP-Br1 is identical to the cyclin-dependent kinase 4 (cdk4)-binding protein p34(SEI

216 nknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cycli

217 Cyclin D-Cyclin-Dependent Kinase 4 (CDK4)-dependent phosphorylati

218 The p16ink4a-cyclin D1/cyclin-dependent kinase 4 (Cdk4)-retinoblastoma (Rb) pat

219 in has been reported to be phosphorylated by cyclin-dependent kinase 4 (cdk4).

220 pproach revealed a specific interaction with cyclin-dependent kinase 4 (CDK4).

221 e the phosphorylation of Rb, by binding with cyclin-dependent kinase 4 (CDK4).

222 thway negatively regulates the expression of cyclin-dependent kinase 4 (CDK4).

223 le the function was assayed by inhibition of cyclin-dependent kinase 4 (CDK4).

224 that operates during G1 phase by activating cyclin-dependent kinase 4 (Cdk4).

225 n that was mediated by the neo-expression of cyclin-dependent kinase 4 (CDK4).

226 ilaggrin and downregulation of cyclin D1 and cyclin-dependent kinase 4 (CDK4).

227 The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD033299

228 des the p16 (encoded by the CDKN2A gene) and cyclin-dependent kinase 4 (cdk4, encoded by the CDK4 gen

229 sed cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 (cdk4) activity.

230 n the aberrant region-specific expression of cyclin-dependent kinase-4 (cdk4) and -6 (cdk6), growth d

231 nhanced the kinase activity of the cyclin D1-cyclin-dependent kinase-4 (cdk4) complex.

232 us study, we reported that overexpression of cyclin-dependent kinase-4 (CDK4) in mouse epidermis resu

233 Newly synthesized cyclin D1 assembled with cyclin-dependent kinase-4 (CDK4) to form holoenzyme comp

234 Inhibition of the cell cycle kinase, cyclin-dependent kinase-4 (Cdk4), is expected to provide

235 rresting cells in the G1 phase by inhibiting cyclin-dependent kinases 4 (Cdk4) and 6 (Cdk6), thus pre

236 ts antitumor actions led to the inhibitor of cyclin-dependent kinase 4, CDKN2A.

237 An increase in cyclin D1/cyclin-dependent kinase 4 complex was also demonstrated

238 C12 myoblasts by transient activation of the cyclin-dependent kinase 4 complex, subsequent phosphoryl

239 KN2 encodes a specific inhibitor of cyclin D-cyclin-dependent kinase 4 complexes important in cell-cy

240 equestered by high levels of active cyclin D/cyclin-dependent kinase 4 complexes.

241 ich is involved in the assembly of cyclin D1/cyclin-dependent kinase-4 complexes, was increased by DH

242 is resistant to both CycE/cdk2 and Cyclin D/cyclin-dependent kinase 4 (CycD/cdk4).

243 xO activation were found to be inhibition of cyclin-dependent kinase 4, cyclin-dependent kinase 6, an

244 in the levels of the p16(INK4a), p27(KIP1), cyclin-dependent kinase 4, cyclin-dependent kinase 6, gl

245 se 4 proteins, and a concomitant decrease in cyclin-dependent kinase 4/cyclin D1 associated kinase ac

246 and p27 was increased while the activity of cyclin-dependent kinase 4 decreased.

247 ction depends on three cyclin D1 activities: cyclin-dependent kinase 4-dependent kinase activity, tit

248 ormation after transduction with telomerase, cyclin-dependent kinase 4, dominant-negative p53, and ac

249 ll cycle arrest in A431 cells is mediated by cyclin-dependent kinase 4 downregulation.

250 antigen overexpression and abnormalities in cyclin-dependent kinase 4, epidermal growth factor recep

251 The INK4 (inhibitor of cyclin-dependent kinase 4) family consists of four tumor

252 at proteins including the INK4 (inhibitor of cyclin-dependent kinase 4) family have been reported rec

253 blastoma protein and no amplification of the cyclin-dependent kinase 4 gene.

254 iated with DNA repair capacity for two hTERT/cyclin-dependent kinase 4, immortalized bronchial epithe

255 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.

256 hat both an alternative EGFR inhibitor and a cyclin-dependent kinase 4 inhibitor led to significant i

257 se, but increased expression of inhibitor of cyclin dependent kinase 4 (INK4) family cell cycle inhib

258 hyperaccumulation of active cyclin D1.CDK4 (cyclin-dependent kinase 4) kinase.

259 esult that may be due to an effect of p16 on cyclin-dependent kinase 4 levels and IL-12 secretion by

260 ed with induction of the INK4 (inhibitors of cyclin dependent kinase 4) locus leading to cell-cycle a

261 D1 suggests that cyclin D1 or its associated cyclin-dependent kinase 4 may be useful targets in the t

262 Furthermore, induction of cyclin D and cyclin-dependent kinase 4 mRNA and protein was blocked u

263 hibitor, Gleevec, which blocked cyclin D and cyclin-dependent kinase 4 nuclear translocation.

264 ration or overexpression of the cyclin D1 or cyclin-dependent kinase 4 oncoproteins.

265 rd Hospital and clinics since 2008 receiving cyclin dependent kinase 4 or 6 (CDK4/6) inhibitors, poly

266 as two indolocarbazole-derived inhibitors of cyclin-dependent kinase 4 or 6 induced deletion of the f

267 ease unless it is responding to increases in cyclin-dependent kinase-4 or other cell cycle regulators

268 ation of cyclin D1 expression, inhibition of cyclin-dependent kinases 4 or 2 activity by small molecu

269 ves binding to and inactivating the cyclin D-cyclin-dependent kinase 4 (or 6) complex, and thus rende

270 p27(Kip1) loss with epithelial cell-specific cyclin-dependent kinase 4 overexpression identifies the

271 We examined the expression of the cyclin-dependent kinase 4, p34PSK-J3/cdk4 protein, in sm

272 oliferating cell nuclear antigen, cyclin D1, cyclin-dependent kinase 4, p53, cytokeratin 14, epiderma

273 on of several important molecules, including cyclin-dependent kinase 4, p53, mouse double minute 2 (M

274 ction of HSP72 and depletion of ERBB2, CRAF, cyclin-dependent kinase 4, phospho-AKT/total AKT, and hy

275 d the decrease in cyclin D1, D2, and D3, and cyclin-dependent kinase 4 protein.

276 ed a decrease in cyclins D1, D2, and D3, and cyclin-dependent kinase 4 proteins, and a concomitant de

277 21 and decreased expression of cyclin D1 and cyclin-dependent kinase 4 proteins.

278 human malignancies, and p16(INK4a)-cyclin D1-cyclin-dependent kinase 4-RB pathway aberrations are pre

279 ependent kinase 2 mutants bearing equivalent cyclin-dependent kinase 4 residues, namely F82H, L83V, H

280 Assay of the mutants with a cyclin-dependent kinase 4-selective bisanilinopyrimidine

281 cyclin-dependent kinase 2-specific, but not cyclin-dependent kinase 4-specific, sites in a p21-depen

282 er hand, the late induction of cyclin D1 and cyclin-dependent kinase 4 was indicative of possible cel

283 y regulates LIC-related genes, including the cyclin-dependent kinase 4, which is a crucial modulator